Lista de obras - Joanna Góra-Tybor - Dominio Público Uruguay

2-Chlorodeoxyadenosine (2-CDA) does not Change the Expression of Fas Antigen on Chronic Lymphocytic Leukaemia Cells ⬇️

artículo científico publicado el 1 de enero de 2000

A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor-alpha and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice

artículo científico publicado en 1994

A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry

artículo científico publicado en 2017

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

artículo científico publicado en 1997

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group

artículo científico publicado en 2009

Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology

scientific article published in 2020

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia

artículo científico publicado en 2005

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

scientific article published on 21 March 2006

Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies

scientific article published on 01 February 2000

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

artículo científico publicado en 2001

Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

artículo científico publicado en 2007

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2002

Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia

artículo científico publicado en 2001

Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia

artículo científico publicado en 2002

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

artículo científico publicado en 2007

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

artículo científico publicado en 2001

Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.

artículo científico publicado en 2014

Clonal proliferation of large granular lymphocytes -- LGL leukemia

artículo científico publicado el 1 de enero de 1995

Coexistence of chronic lymphocytic leukemia and essential thrombocythemia

artículo científico publicado en 2003

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

artículo científico publicado en 1999

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry

artículo científico publicado en 2018

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

artículo científico publicado en 2010

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

artículo científico publicado en 2005

Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

artículo científico publicado en 2020

Effect of platinum(II) choline complex on murine leukemias L1210 and P388

artículo científico publicado el 1 de julio de 1997

Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies

artículo científico publicado en 2009

Emerging Therapies in Chronic Myeloid Leukemia ⬇️

artículo científico publicado el 1 de junio de 2012

Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma.

artículo científico publicado en 1996

Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms

artículo científico publicado en 2020

Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.

artículo científico publicado en 2013

Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210

scientific article published on 01 January 1994

Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia

artículo científico publicado en 2007

Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.

artículo científico publicado en 2013

Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine

artículo científico publicado en 2012

Preface

Preface to a supplement to Pharmacy World on the 5TH Symposium of the European Society for the Study of Purine & Pyrimidtne Metabolism in Man (ESSPPMM 1995)

Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia

artículo científico publicado en 2010

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.

artículo científico publicado en 2017

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment

artículo científico publicado en 2002

Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.

artículo científico publicado en 2015

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

artículo científico publicado en 2022

Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma

artículo científico publicado el 1 de junio de 2013

Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia

artículo científico publicado en 2005

Richter's syndrome in the brain first manifested as an ischaemic stroke

artículo científico publicado en 2004

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

artículo científico publicado en 2004

Ruksolitynib w terapii chorych na mielofibrozę — pytania i odpowiedzi

artículo científico publicado en 2019

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

artículo científico publicado en 2004

Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation ⬇️

artículo científico publicado el 1 de febrero de 1998

Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388

scientific article published on 01 January 1993

Targeted drugs in chronic myeloid leukemia.

artículo científico publicado en 2008

The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis ⬇️

artículo científico publicado el 1 de enero de 1994

The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

artículo científico publicado en 2005

The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor-alpha or its mutein on murine leukaemias L1210 and P388.

artículo científico publicado en 1995

The influence of 2-chlorodeoxyadenosine alone and in combination with cyclophosphamide or methotrexate on normal hematopoiesis in mice

artículo científico publicado en 1993

The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.

artículo científico publicado en 2013

The influence of recombinant human tumor necrosis factor (rh-TNF alpha) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic leukaemic blasts (CFU-L) in cultures in vitro

artículo científico publicado el 1 de enero de 1992

The interaction of 2-chlorodeoxyadenosine (2-CDA) and interferon alpha (IFN-alpha) on normal and myeloid leukemia hematopoiesis in vitro

scientific article published on 01 April 1994

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

artículo científico publicado en 1998

The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.

artículo científico publicado en 1998

Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.

artículo científico publicado en 2001

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors

artículo científico publicado en 2017

Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF)

artículo científico publicado en 1996

[Apoptosis--programmed cell death]

artículo científico publicado en 1994

[Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)]

artículo científico publicado en 1996

[Clinical pharmacology of hydroxyurea]

artículo científico publicado en 1995

[Importance of physician-patient relations in therapeutic process of patients with hematological neoplasms]

artículo científico publicado en 2014

[Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia]

scientific article published on 01 January 2006

Lista de obras de Joanna Góra-Tybor

2-Chlorodeoxyadenosine (2-CDA) does not Change the Expression of Fas Antigen on Chronic Lymphocytic Leukaemia Cells ⬇️

A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor-alpha and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice

A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group

Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia

Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.

Clonal proliferation of large granular lymphocytes -- LGL leukemia

Coexistence of chronic lymphocytic leukemia and essential thrombocythemia

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

Effect of platinum(II) choline complex on murine leukemias L1210 and P388

Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies

Emerging Therapies in Chronic Myeloid Leukemia ⬇️

Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia

Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma.

Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms

Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.

Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210

Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia

Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.

Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine

Preface

Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment

Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma

Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia

Richter's syndrome in the brain first manifested as an ischaemic stroke

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

Ruksolitynib w terapii chorych na mielofibrozę — pytania i odpowiedzi

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation ⬇️

Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388

Targeted drugs in chronic myeloid leukemia.

The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis ⬇️

The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor-alpha or its mutein on murine leukaemias L1210 and P388.

The influence of 2-chlorodeoxyadenosine alone and in combination with cyclophosphamide or methotrexate on normal hematopoiesis in mice

The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.

The influence of recombinant human tumor necrosis factor (rh-TNF alpha) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic leukaemic blasts (CFU-L) in cultures in vitro

The interaction of 2-chlorodeoxyadenosine (2-CDA) and interferon alpha (IFN-alpha) on normal and myeloid leukemia hematopoiesis in vitro

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.

Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors

Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF)

[Apoptosis--programmed cell death]

[Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)]

[Clinical pharmacology of hydroxyurea]

[Importance of physician-patient relations in therapeutic process of patients with hematological neoplasms]

[Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia]